Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
about
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical reviewChemotherapy options in castration-resistant prostate cancerNeutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-AnalysisPreoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study.A robust blood gene expression-based prognostic model for castration-resistant prostate cancerBlood-based gene expression profiling in castrate-resistant prostate cancer.Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsyPreoperative Neutrophil-to-lymphocyte Ratio Predicts Long-term Survival in Patients Undergoing Total Laryngectomy With Advanced Laryngeal Squamous Cell Carcinoma: A Single-center Retrospective Study.Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical ProstatectomyRole of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillancePrognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients.Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis.Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer.Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Author reply: The neutrophil-to-lymphocyte ratio in clinical practice.Neutrophils in cancer: prognostic role and therapeutic strategies.Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder CancerThe prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.Neutrophil-lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer.Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.Nomograms for prognostic factors of spinal giant cell tumor combining traditional clinical characteristics with inflammatory biomarkers after gross total resection.Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.Current treatment strategies for advanced prostate cancer.Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients.Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker.Liquid biopsies and plasma DNA: paving the way for personalized medicine in metastatic castration-resistant prostate cancer.Diagnostic Gleason score and castration-resistant prostate cancer.Prognostic significance of Ki67 expression and the derived neutrophil-lymphocyte ratio in nasopharyngeal carcinoma.Neutrophil-lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis
P2860
Q28073742-FCBF9F94-4AA2-4235-B0D1-A033DB396AA8Q28078477-781EB66E-9765-4C0F-A3A5-3FBC5335983EQ28552296-447B95EF-1C01-4E83-9C79-D786D48D59F0Q33798830-0BCF78F4-67EC-4D5D-B683-8F27F6F46C35Q35752837-439B22EA-57BC-41A0-8A89-7D241298BB95Q35772012-E74C7BF2-3461-40FD-A2CE-3FC3D5EA3200Q36544801-C8402196-0421-4507-8DFD-6FEEEB7ED557Q36580936-3057C1B6-54FA-4B56-83C7-E0B9810CC377Q36864218-EA8804C2-DA60-4E7B-AA20-1F5F4B891EBDQ37585270-F3FFB7B5-D984-42FC-85FD-A8F7C78BF57BQ38487988-D9335AB3-88C4-43CB-9F91-ABD0F15BD487Q38623275-EF309362-56EF-4286-B37D-357171A529C8Q38729853-5788C62F-1F4F-447C-BDB9-1F2CD785462FQ38936443-1FEBE21F-B12B-4A3E-9FD8-7C48CEF2F83DQ38978620-E3959F1B-97E5-4B03-8EBE-AA18658649D4Q39031750-E3570E6C-9385-4ABD-9D3B-9C2CD4156770Q39041165-2CC18531-F767-4B0F-B26D-3786D914707CQ39349569-64C15BE3-EC75-4C9E-81FA-E9424E060A11Q39641273-B9699AE7-68F4-40B5-8B7F-9C3BA6CBC9B7Q39651226-673AEB79-6BBC-4D02-80CE-3899FD2B9187Q40332155-B88708EF-B40B-483C-815A-E940B01B92B3Q40460665-DF4F8F1D-8A92-4049-9A10-5953B206BB14Q41431390-7DAD0AA3-84F1-4278-A395-E1CDC4FE77AFQ41472948-E520C6CD-1BC8-42CD-85E6-957EC8A3616CQ41777743-C4CA7D9B-4938-4C20-B8B0-2DD6CB7EFC8EQ42152624-0A2C52F7-AFBC-4ECD-9E72-25A3E52314AFQ42674196-B639D80E-365C-4961-9B3E-DBC0A357512DQ43144351-22CC7250-3163-449E-A09A-851955429DEAQ45287349-CF489039-A440-4E47-A2BD-DB9C9B2470DFQ47122549-F4FD9806-47D7-4D9B-B55C-FD54C658FF19Q47152345-08B39F9A-7B55-4461-97E8-D21B5E4F5C5DQ48167919-40ABF1F0-B7AF-4AF4-952F-4DAC41B67373Q48561494-97479F01-50BC-4612-8C65-110505AB0B36Q49084411-02161625-56F7-4A6A-98D0-8399A23484C0Q52602665-16E94ABC-4ABC-4F22-B832-4901F975DD02Q52730098-8CC40885-D6A9-4403-B9EF-D9E8561AB0F1Q53741855-58CFC034-2281-4CF7-8F21-769DE1E40A77Q53789514-C3FD48A8-8E6B-44BA-AB67-FBDE8B804217Q55709763-9BF475B5-EE18-4BBB-AFC9-228307F9C3C7Q57074276-9703FDEA-A633-481F-9D49-6E48A0630900
P2860
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Neutrophil-to-lymphocyte ratio ...... o randomized phase III trials.
@ast
Neutrophil-to-lymphocyte ratio ...... o randomized phase III trials.
@en
type
label
Neutrophil-to-lymphocyte ratio ...... o randomized phase III trials.
@ast
Neutrophil-to-lymphocyte ratio ...... o randomized phase III trials.
@en
prefLabel
Neutrophil-to-lymphocyte ratio ...... o randomized phase III trials.
@ast
Neutrophil-to-lymphocyte ratio ...... o randomized phase III trials.
@en
P2093
P2860
P921
P356
P1433
P1476
Neutrophil-to-lymphocyte ratio ...... wo randomized phase III trials
@en
P2093
A J Templeton
F E Vera-Badillo
G Sonpavde
I F Tannock
M A Eisenberger
M Rosenthal
P2860
P304
P356
10.1093/ANNONC/MDU569
P577
2014-12-15T00:00:00Z